Investor Overview

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first in class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.

Our most advanced in-house drug candidate is OATD-01, a first in class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.

Our second proprietary candidate is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase 1 clinical development in the second half of 2022.

Investor Overview

Our Business Model

  • Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization The preferred stage of development for out-licensing is early clinical Proof of Concept.
  • Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both mRNA and proteins – needed to generate a pipeline of first-in-class drug candidates.
  • Our approach to drug discovery is based on bold target selection, both mRNA and proteins, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
  • Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.

 

Investor's calendar

DATE EVENT
March 31, 2022.Publication of the Company's Annual Reports for the year 2021 (separate and consolidated)
April 29, 2022.Publication of the Company’s quarterly report for I quarter of 2022
September 30, 2022.Publication of the Company’s semi-annual report for I half of 2022
October 31, 2022.Publication of the Company’s quarterly report for III quarter of 2022

Stock Quotes


Shareholding Structure

Shareholders

 THE NUMBER OF ACTIONSNUMBER OF VOTESSHARE IN THE SHARE CAPITALSHARE IN THE NUMBER OF VOTES
BLACK FOREST SICAV - SIF societe anonyme * together with FTF Columbus Sp. z o. o., including:4 175 0004 175 00029,76%29,76%
BLACK FOREST SICAV - SIF societe anonyme * directly:4 135 0004 135 00029,47%29,47%
Indirectly through FTF Columbus Sp. z o. o40 00040 0000,29%0,29%
Marcin Szumowski together with Szumowski Investments sp. Z oo1 070 0001 070 0007,63%7,63%
Nationale-Nederlanden Universal Pension Society SA845 000845 0006,02%6,02%
The rest7 940 0007 940 00056,59%56,59%
TOTAL140 300 000140 300 000100,00%100,00%

* Members of the Management Board, Supervisory Board and shareholders of the Company do not hold any shares of BLACK FOREST SICAV-SIF societe anonyme. The indirect owner of the shares is Michał Andrzej Sołowow. ** * 70,000 shares have not yet been admitted to trading.

Share in capital and number of votes

Marcin Szumowski together with Szumowski Investments sp. Z oo Nationale-Nederlanden Universal Pension Society SA BLACK FOREST SICAV - SIF societe anonyme * Other

Financial Information

Financial Report

ON the WSE FROM

April 19, 2018

MARKET / QUOTATION SEGMENT

WSE / Parallel

SECTOR (WSE)

Biotechnology

INDEX AFFILIATION

WIG-Poland, WIG

WSE TICKER

POWER

ISIN

PLONCTH00011

NUMBER OF SHARES ISSUED

140,300

Contact

Contact with the media and individual investors

Michał Wierzchowski

CC GROUP

+48 531 613 067 +48 531 613 067
michal.wierzchowski@ccgroup.pl

Contact with institutional investors and sell-side analysts

Katarzyna Mucha

CC GROUP

+48 697 613 712 +48 22 440 1 440
katarzyna.mucha@ccgroup.pl
This site is registered on wpml.org as a development site.